US › Healthcare

Sol Gel Technologies Ltd (SLGL)

US · Healthcare · Biotechnology

$84.50+3.06%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$108,000
Revenue YoY
-89.5%
Net profit
$-3.7M
Profit YoY
+57.7%
EPS
$-1.31
EPS estimate
$-1.63
Net margin
-3,450.9%

EPS came in at -1.31 against a street estimate of -1.63 — a beat of 19.6%.

Key statistics

Market cap
$268.9M
Forward P/E
9.3
P/B
5.33
Book value
$15.72
EPS (TTM)
$-0.30
52-week high
$97.97
52-week low
$12.66
50-day MA
$76.00
200-day MA
$64.16
Beta
1.13

Analyst view

Analysts rate Sol Gel Technologies Ltd a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $193.00.

Shareholding

Insiders
59.70%
Institutions
37.37%

Largest institutional holders

FundStake
Opaleye Management Inc15.30%
Great Point Partners LLC8.39%
Phoenix Financial Ltd6.45%
Trails Edge Capital Partners, LP2.62%
Citadel Advisors Llc1.14%
Affinity Asset Advisors, LLC1.07%
Squadron Capital Management LLC0.95%
Stonepine Capital Management Llc0.85%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Sol Gel Technologies Ltd — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.